Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Fenghuang Zhan to Disease-Free Survival

This is a "connection" page, showing publications Fenghuang Zhan has written about Disease-Free Survival.

 
Connection Strength
 
 
 
0.179
 
  1. Gao M, Kong Y, Wang H, Xie B, Yang G, Gao L, Zhang Y, Zhan F, Dai B, Tao Y, Shi J. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. Tumour Biol. 2016 Aug; 37(8):11081-98.
    View in: PubMed
    Score: 0.031
  2. Li Z, Li F, Yi S, Gu Z, Yu Z, Xu Y, Feng X, Liu W, Zou D, Qi J, Zhan F, Qiu L. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer. 2015 Jul 29; 15:555.
    View in: PubMed
    Score: 0.030
  3. Salem K, McCormick ML, Wendlandt E, Zhan F, Goel A. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol. 2015; 4:23-33.
    View in: PubMed
    Score: 0.028
  4. Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015 Apr 15; 136(8):1835-44.
    View in: PubMed
    Score: 0.028
  5. An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014 Feb; 99(2):353-9.
    View in: PubMed
    Score: 0.026
  6. Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD, Potti A. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol. 2009 Sep 01; 27(25):4197-203.
    View in: PubMed
    Score: 0.020
  7. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006 Apr; 9(4):313-25.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.